Recent News
Tirzepatide Shows Powerful Diabetes-Prevention Effect in Three-Year Trial
Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to the results of a new study led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, Yale School of Medicine and other institutions.
From Intervention to Prevention: The Latest Innovations and Expertise from TCT 2024
The Transcatheter Cardiovascular Therapeutics (TCT) conference has long been one of the top educational forums in interventional cardiovascular medicine.
Weill Cornell Medicine Receives Grant to Fund Pain Control Research for Critically Ill Children
Dr. Chani Traube, the Gerald M. Loughlin, MD Professor of Pediatrics at Weill Cornell Medicine, has been awarded a $3.4 million grant, with the possibility of extending to a total of $17 million over five years, from the National Institutes of Health, for a large-scale clinical trial called Optimizing Pain Treatment in Children on Mechanical ventilation (OPTICOM).
In Pioneering Study, Gene Technology Outperforms Standard Newborn Screening Tests
Early results from 4,000 babies in the GUARDIAN study show that genome sequencing picks up many more serious health conditions than standard newborn screening and is favored by most parents.
NewYork-Presbyterian Launches Historic Fundraising Campaign
NewYork-Presbyterian announced the launch today of one of the most ambitious initiatives in its 250-year history: the $2 billion For Every Future campaign.
Featured Stories
Health Matters 7 Min Read